[HTML][HTML] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
Background The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[PDF][PDF] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse, AR Synnes… - 2013 - scienceopen.com
Background: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[PDF][PDF] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse, AR Synnes… - 2013 - Citeseer
Background: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[PDF][PDF] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse, AR Synnes… - 2013 - academia.edu
Background: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[PDF][PDF] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse, AR Synnes… - 2013 - cyberleninka.org
Background: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[引用][C] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse… - BMC Health Services …, 2013 - kclpure.kcl.ac.uk
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis — King's College
London Skip to main navigation Skip to search Skip to main content King's College London …
London Skip to main navigation Skip to search Skip to main content King's College London …
[PDF][PDF] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee, C Mitton, M Kruse, AR Synnes… - 2013 - core.ac.uk
Background: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.
CD Bickford, LA Magee, C Mitton… - BMC Health …, 2013 - openaccess.sgul.ac.uk
BACKGROUND: The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.
CD Bickford, LA Magee, C Mitton, M Kruse… - BMC Health Services …, 2013 - europepmc.org
Background The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …
[HTML][HTML] Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
CD Bickford, LA Magee… - BMC Health …, 2013 - bmchealthservres.biomedcentral …
The aim of this study was to assess the cost-effectiveness of administering magnesium
sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either imminent or …
sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either imminent or …